C o m m e n t a r y
Patients with MUPS are common in primary and secondary care. Increasing evidence exists that such psychological therapies as cognitive behavior therapy (CBT) are effective in the treatment of these symptoms (1, 2) . Unfortunately, suitably trained therapists are scarce, and psychological therapy is unacceptable to some patients. Thus, effective pharmacologic therapies have a potentially substantial role in the treatment of patients with MUPS.
The review by O'Malley and colleagues supports the use of antidepressants for treating MUPS. The number needed to treat of 4 for short-term improvement is clinically significant and is similar to that obtained with CBT (1, 2). Persons with a wide range of MUPS seem to benefit from antidepressants, even though not all are depressed. An important caveat is that most evidence applies to patients in secondary care who have chronic symptoms.
Clinicians therefore have 2 evidence-based types of therapy for MUPS: psychological (CBT) and pharmacologic (antidepressants). If CBT is available, the choice between it and antidepressants is difficult. Patient choice should therefore be encouraged because compliance with and enthusiasm for the chosen therapy may profoundly influence outcome. Persons with MUPS who reject psychological therapy, however, may also reject the use of antidepressants for "physical" problems.
The term "antidepressants" is unhelpful in this situation and is increasingly inappropriate as evidence for other indications accumulates.
Several 
S t u d y s e l e c t i o n
2 reviewers independently selected studies that were randomized controlled trials (RCTs) (including crossover trials), involved adults with MUPS, compared antidepressants with placebo or a nonantidepressant intervention, reported measurable outcomes, and were published in English.
D a t a e x t r a c t i o n
Data extracted included symptoms, setting, treatment (regimens and follow-up), patient characteristics, assessment of comorbid psychiatric disease, adverse effects, outcomes, statistical analysis of reported results, and quality of study methods (Jadad scale).
M a i n r e s u l t s 94 RCTs on 6 symptom syndromes met the selection criteria. 6595 patients (76% women) were studied for a median of 9 weeks. The dropout rate was > 20% in 40% of the RCTs. A meta-analysis combined results for improvement: global assessment (patient or physician), summary symptom index scores, or pain-severity scale scores (Table) . 4 patients (95% CI 3 to 7) would need to be treated to improve 1 additional patient's condition. A meta-analysis of the results for continuous outcomes reported a pooled standardized mean difference of 0.87 (CI 0.59 to 1.14).
C o n c l u s i o n
In patients with medically unexplained physical symptoms or syndromes, antidepressants are effective for improving outcomes, including symptoms and disability. 
